NEW YORK (360Dx) – Bluejay Diagnostics said today that it has entered into a two-year cooperative research and development agreement (CRADA) with the US Naval Medical Research Center to develop a non-invasive point-of-care test for early-stage detection of Lyme disease.
The collaboration will focus on the study of antigens associated with various pathogens and identifying the most immunoreactive antigen — information that the collaborators will use to develop a rapid test for the detection of pathogen antigens in biofluids, including serum and urine.
Financial and other terms of the agreement were not disclosed.
The agreement will be completed in four phases to identify the most pertinent antigen; confirm sensitivity and specificity; generate specific highly-efficient antibodies; and provide a proof-of-concept test on the platform technology, Acton, Massachusetts-based Bluejay said.
The rapid test will use Bluejay's immunochromatography and laminar flow platform, which has been cleared by the US Food and Drug Administration.
Bluejay Diagnostics CEO Neil Dey said in a statement that he anticipates the collaboration with the Navy will also enable the pursuit of developing other tests for infectious diseases.